Structure Therapeutics In... (GPCR)
19.90
-0.10 (-0.50%)
At close: Mar 27, 2025, 3:59 PM
19.80
-0.50%
Pre-market: Mar 28, 2025, 05:48 AM EDT
-0.50% (1D)
| Bid | 19.7 |
| Market Cap | 380M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.08M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -8.65 |
| Forward PE | -40.56 |
| Analyst | Buy |
| Ask | 20.5 |
| Volume | 554,028 |
| Avg. Volume (20D) | 803,145 |
| Open | 19.81 |
| Previous Close | 20.00 |
| Day's Range | 19.61 - 20.44 |
| 52-Week Range | 19.39 - 62.74 |
| Beta | -2.52 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral sma...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2023
Employees 163
Stock Exchange NASDAQ
Ticker Symbol GPCR
Website https://structuretx.com
Analyst Forecast
According to 9 analyst ratings, the average rating for GPCR stock is "Buy." The 12-month stock price forecast is $83.5, which is an increase of 319.60% from the latest price.
Stock Forecasts6 months ago
+1.03%
Structure Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
8 months ago
-1.15%
Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.
